These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15351209)

  • 21. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Chaix ML; Ekouevi DK; Peytavin G; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Amani-Bosse C; Menan H; Leroy V; Rouzioux C; Dabis F
    Antimicrob Agents Chemother; 2007 Mar; 51(3):896-901. PubMed ID: 17178792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
    Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
    Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
    Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
    J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
    Roquebert B; Wirden M; Simon A; Deval J; Katlama C; Calvez V; Marcelin AG
    J Med Virol; 2007 Mar; 79(3):207-11. PubMed ID: 17245724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
    Liu L; Lu HZ; Henry M; Tamalet C
    J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naïve patients in Accra, Ghana.
    Sagoe KW; Dwidar M; Lartey M; Boamah I; Agyei AA; Hayford AA; Mingle JA; Arens MQ
    J Clin Virol; 2007 Oct; 40(2):163-7. PubMed ID: 17827059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
    Paintsil E; Margolis A; Collins JA; Alexander L
    J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
    Soriano V
    Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
    Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
    J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
    Yaotsè DA; Nicole V; Roch NF; Mireille PD; Eric D; Martine P
    Infect Genet Evol; 2009 Jul; 9(4):646-52. PubMed ID: 19460333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals.
    Torti C; Bono L; Gargiulo F; Uccelli MC; Quiros-Roldan E; Patroni A; Paraninfo G; Tirelli V; Manca N; De Francesco MA; Perandin F; Carosi G
    Clin Microbiol Infect; 2004 Sep; 10(9):826-30. PubMed ID: 15355414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase.
    Berkhout B; Back NK; de Ronde A; Jurriaans S; Bakker M; Parkin NT; van der Hoek L
    AIDS; 2006 Jul; 20(11):1515-20. PubMed ID: 16847406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
    Pernas M; López-Galíndez C
    Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
    Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.